Business
Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL)...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future MilestonesCalgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient (\"API\") of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices (\"cGMP\") run of its multi-kilogram batches of MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. (\"Ausun\"). The engineering run will provide the Company with a batch of its lead drug candidate MB-204 that can be used in good laboratory practise (\"GLP\") toxicology studies, which are scheduled to begin in Q4 2021. Ausun will also be providing the Company with a cGMP batch of MB-204 that ensures identity, quality and purity in preparation of entering Phase I clinical studies in 2022 following the completion of the Company's toxicology studies. \"To date we have shown in a number of pre-clinical studies the level of efficacy and safety MB-204 can deliver,\" said Rod Matheson, Chief executive Officer of Marvel. \"With the partnership we have in place with Ausun, we have now entered a key and very important stage in the development of MB-204 to drive this asset into clinical studies. These milestones are key in further advancing our discussions with potential commercial partners to ensure the best outcome for our shareholders.\" Marvel's lead compound asset MB-204 (\"MB-204\") is being developed for neurological conditions such as depression and anxiety, Alzheimer's and ADHD. Marvel's compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson's disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor (\"A2aR\"). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration.The upcoming Company milestones for its lead compound asset MB-204 include:Completion of 2 kg of e...